Abbott Laboratories $ABT Holdings Reduced by Cidel Asset Management Inc.

Cidel Asset Management Inc. reduced its stake in Abbott Laboratories (NYSE:ABT) by 4.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 322,225 shares of the healthcare product maker’s stock after selling 13,616 shares during the quarter. Abbott Laboratories makes up approximately 2.9% of Cidel Asset Management Inc.’s investment portfolio, making the stock its 7th largest position. Cidel Asset Management Inc.’s holdings in Abbott Laboratories were worth $40,372,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Harbor Capital Advisors Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at about $27,000. Cloud Capital Management LLC acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the 3rd quarter valued at about $31,000. Delos Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories in the 2nd quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC acquired a new stake in shares of Abbott Laboratories during the 3rd quarter worth approximately $33,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Abbott Laboratories Stock Down 0.0%

NYSE:ABT opened at $102.84 on Monday. Abbott Laboratories has a 52 week low of $100.88 and a 52 week high of $139.06. The stock’s fifty day moving average is $109.48 and its two-hundred day moving average is $120.94. The stock has a market capitalization of $179.11 billion, a price-to-earnings ratio of 27.65, a price-to-earnings-growth ratio of 1.64 and a beta of 0.79. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The business had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. During the same quarter last year, the firm posted $1.34 earnings per share. The business’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a $0.63 dividend. This represents a $2.52 annualized dividend and a dividend yield of 2.5%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is presently 67.74%.

Insider Transactions at Abbott Laboratories

In other news, VP John A. Jr. Mccoy sold 585 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $67,614.30. Following the completion of the transaction, the vice president owned 24,628 shares in the company, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total value of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,055 shares of company stock valued at $353,097 in the last 90 days. Insiders own 0.46% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently commented on the company. Daiwa Securities Group decreased their price objective on Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a report on Friday, January 30th. The Goldman Sachs Group reduced their target price on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday, January 23rd. Evercore decreased their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Citigroup cut their price objective on Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating for the company in a research report on Wednesday, March 11th. Finally, BTIG Research reduced their price objective on shares of Abbott Laboratories from $140.00 to $131.00 and set a “buy” rating on the stock in a report on Tuesday, March 31st. Two research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $135.68.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.